Long-Term Side Effects of Ozempic: Multi-Peptide Market Safety Data Analysis
Title: Long-Term Side Effects of Ozempic: Multi-Peptide Market Safety Data Analysis Abstract: Analysis of long-term Ozempic (semaglutide) side effects, including gastrointestinal motility disorders and muscle loss, reveals critical safety data for the multi-peptide market. Current trends show a shift toward GLP-1/GIP dual agonists with improved tolerability. Comparative brand analysis (Novo Nordisk vs. Eli Lilly) highlights differences in half-life and cardiovascular outcomes. Technical advantages include potent glycemic control; disadvantages involve high cost and injection-site reactions. Product parameters, regulatory certifications (FDA/EMA), and logistics (cold-chain compliance) are evaluated. Industry data projects a 15% CAGR, emphasizing rigorous supplier audits for peptide purity and stability.